Prognostic Factors of Stroke-Like Migraine Attacks after Radiation Therapy (SMART) Syndrome.


Journal

AJNR. American journal of neuroradiology
ISSN: 1936-959X
Titre abrégé: AJNR Am J Neuroradiol
Pays: United States
ID NLM: 8003708

Informations de publication

Date de publication:
03 2022
Historique:
received: 26 07 2021
accepted: 10 12 2021
pubmed: 19 2 2022
medline: 28 4 2022
entrez: 18 2 2022
Statut: ppublish

Résumé

Prognostic factors of stroke-like migraine attacks after radiation therapy (SMART) syndrome have not been fully explored. This study aimed to assess clinical and imaging features to predict the clinical outcome of SMART syndrome. We retrospectively reviewed the clinical manifestations and imaging findings of 20 patients with SMART syndrome (median age, 48 years; 5 women) from January 2016 to January 2020 at 4 medical centers. Patient demographics and MR imaging features at the time of diagnosis were reviewed. This cohort was divided into 2 groups based on the degree of clinical improvement (completely versus incompletely recovered). The numeric and categoric variables were compared as appropriate. There were statistically significant differences between the completely recovered group ( Age, use of steroid treatment at the diagnosis of SMART syndrome, and MR imaging findings of abnormal susceptibility signal, restricted diffusion, and subcortical WM change in the acute SMART region can be prognostic factors in SMART syndrome.

Sections du résumé

BACKGROUND AND PURPOSE
Prognostic factors of stroke-like migraine attacks after radiation therapy (SMART) syndrome have not been fully explored. This study aimed to assess clinical and imaging features to predict the clinical outcome of SMART syndrome.
MATERIALS AND METHODS
We retrospectively reviewed the clinical manifestations and imaging findings of 20 patients with SMART syndrome (median age, 48 years; 5 women) from January 2016 to January 2020 at 4 medical centers. Patient demographics and MR imaging features at the time of diagnosis were reviewed. This cohort was divided into 2 groups based on the degree of clinical improvement (completely versus incompletely recovered). The numeric and categoric variables were compared as appropriate.
RESULTS
There were statistically significant differences between the completely recovered group (
CONCLUSIONS
Age, use of steroid treatment at the diagnosis of SMART syndrome, and MR imaging findings of abnormal susceptibility signal, restricted diffusion, and subcortical WM change in the acute SMART region can be prognostic factors in SMART syndrome.

Identifiants

pubmed: 35177545
pii: ajnr.A7424
doi: 10.3174/ajnr.A7424
pmc: PMC8910816
doi:

Substances chimiques

Steroids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

396-401

Informations de copyright

© 2022 by American Journal of Neuroradiology.

Références

Eur J Neurol. 2021 Apr;28(4):1316-1323
pubmed: 33159349
Eur J Neurol. 2019 Apr;26(4):639-650
pubmed: 30471162
Neuro Oncol. 2003 Apr;5(2):121-7
pubmed: 12672284
Neurosci Lett. 2010 May 31;476(2):89-93
pubmed: 20385203
J Neuroimaging. 2015 Nov-Dec;25(6):1056-8
pubmed: 25702932
J Neuroendocrinol. 2011 Jul;23(7):601-11
pubmed: 21507085
Am J Case Rep. 2020 Mar 28;21:e921795
pubmed: 32221270
Acta Neurol Belg. 2015 Dec;115(4):807-10
pubmed: 25972059
eNeurologicalSci. 2018 May 23;12:1-4
pubmed: 30003148
Expert Rev Clin Pharmacol. 2011 Mar;4(2):233-42
pubmed: 21666852
Neuro Oncol. 2011 Jul;13(7):775-82
pubmed: 21727213
AJNR Am J Neuroradiol. 2013 Dec;34(12):2298-303
pubmed: 23788601
Cephalalgia. 2006 Sep;26(9):1137-42
pubmed: 16919065
Neuroradiology. 2021 Aug;63(8):1377-1381
pubmed: 33694026
Future Oncol. 2014 May;10(7):1277-97
pubmed: 24947265
Neurology. 2006 Aug 22;67(4):676-8
pubmed: 16707725
J Clin Oncol. 1994 Mar;12(3):627-42
pubmed: 8120563
Epilepsia. 2018 Jan;59(1):259-268
pubmed: 29171011
Ochsner J. 2020 Spring;20(1):6-9
pubmed: 32284676
Neurology. 2013 Sep 10;81(11):1014-7
pubmed: 23935180
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571

Auteurs

Y Ota (Y)

From the Division of Neuroradiology (Y.O., E. Liao, R.K., M.K., A.B., T.M., A.S., A.A.C.) yoshiako@med.umich.edu.

D Leung (D)

Department of Radiology and Division of Neuro-Oncology (D.L.), Department of Neurology, University of Michigan, Ann Arbor, Michigan.

E Lin (E)

Division of Neuroradiology (E. Lin), Department of Radiology, University of Rochester Medical Center, Rochester, New York.

E Liao (E)

From the Division of Neuroradiology (Y.O., E. Liao, R.K., M.K., A.B., T.M., A.S., A.A.C.).

R Kurokawa (R)

From the Division of Neuroradiology (Y.O., E. Liao, R.K., M.K., A.B., T.M., A.S., A.A.C.).

M Kurokawa (M)

From the Division of Neuroradiology (Y.O., E. Liao, R.K., M.K., A.B., T.M., A.S., A.A.C.).

A Baba (A)

From the Division of Neuroradiology (Y.O., E. Liao, R.K., M.K., A.B., T.M., A.S., A.A.C.).

H Yokota (H)

Department of Diagnostic Radiology and Radiation Oncology (H.Y.), Graduate School of Medicine, Chiba University, Chiba, Japan.

G Bathla (G)

Division of Neuroradiology (G.B.), Department of Radiology, University of Iowa Hospitals and Clinics, Iowa City, Iowa.

T Moritani (T)

From the Division of Neuroradiology (Y.O., E. Liao, R.K., M.K., A.B., T.M., A.S., A.A.C.).

A Srinivasan (A)

From the Division of Neuroradiology (Y.O., E. Liao, R.K., M.K., A.B., T.M., A.S., A.A.C.).

A A Capizzano (AA)

From the Division of Neuroradiology (Y.O., E. Liao, R.K., M.K., A.B., T.M., A.S., A.A.C.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH